Drug Profile
Tonogenchoncel-L - Kolon TissueGene
Alternative Names: Invossa; Invossa K Inj.; Invossa K Injection; INVOSSA-K inj; TG C; TGF-beta-1 gene therapy - Kolon TissueGene; TissueGene-C; TissueGene-C(S); Transforming growth factor-beta-1 gene therapy - Kolon TissueGeneLatest Information Update: 28 Dec 2023
Price :
$50
*
At a glance
- Originator TissueGene
- Developer Kolon Life Science; Kolon TissueGene
- Class Cell therapies; Gene therapies
- Mechanism of Action Chondrocytes replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Marketed Osteoarthritis
- Preclinical Intervertebral disc degeneration; Rheumatoid arthritis
Most Recent Events
- 19 Dec 2023 Kolon TissueGene plans a phase I trial for Intervertebral disc degeneration (Treatment-experienced) (Intra-articular, Injection) in USA in November 2025 (NCT06144970)
- 18 Dec 2023 US FDA approves IND application for Tonogenchoncel-L in Intervertebral disc degeneration
- 06 Nov 2023 Kolon TissueGene has patent protection for 'cartilage regeneration using cartilage cells and TGF-β' in China